Cargando…

Assessment of soluble immune mediators as potential biomarkers during immune checkpoint inhibitor therapy

Detalles Bibliográficos
Autores principales:	Matsuo, Norikazu, Azuma, Koichi, Sasada, Tetsuro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2019
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6443006/ https://www.ncbi.nlm.nih.gov/pubmed/30956767 http://dx.doi.org/10.18632/oncotarget.26749

Ejemplares similares

Survival and biomarkers for cachexia in non‐small cell lung cancer receiving immune checkpoint inhibitors
por: Murata, Daiki, et al.
Publicado: (2023)

Unlocking the Potential of Biomarkers for Immune Checkpoint Inhibitors in Cancer Therapy
por: Dal Collo, Giada, et al.
Publicado: (2023)

Predictive value of CD73 expression for the efficacy of immune checkpoint inhibitors in NSCLC
por: Ishii, Hidenobu, et al.
Publicado: (2020)

A Lack of Biomarkers for Cardiac Complications of Immune Checkpoint Inhibitor Therapy
por: Li, Siqi, et al.
Publicado: (2020)

Prognostic effect of cachexia in patients with non‐small cell lung cancer receiving immune checkpoint inhibitors
por: Matsuo, Norikazu, et al.
Publicado: (2023)

Advanced Research on Immune Checkpoint Inhibitor Therapy
por: Imai, Hisao, et al.
Publicado: (2022)

Immune Checkpoint Inhibitors in Uro-Oncology: Urgent Call for Biomarkers
por: Pichler, Renate
Publicado: (2020)

Clinical significance of interstitial lung abnormalities and immune checkpoint inhibitor‐induced interstitial lung disease in patients with non‐small cell lung cancer
por: Murata, Daiki, et al.
Publicado: (2022)

The neurotoxic effects of immune checkpoint inhibitor therapy for melanoma
por: Spain, Lavinia, et al.
Publicado: (2019)

Immune Responses to Epidermal Growth Factor Receptor (EGFR) and Their Application for Cancer Treatment
por: Sasada, Tetsuro, et al.
Publicado: (2016)

Immune checkpoint inhibitors in penile cancer
por: Buonerba, Carlo, et al.
Publicado: (2021)

Cardiotoxicity Associated with Immune Checkpoint Inhibitors
por: Minegishi, Shintaro, et al.
Publicado: (2023)

Evolving cardiac biomarkers for immune checkpoint inhibitor related myocarditis in cancer patients
por: Talukder, Suprateeka, et al.
Publicado: (2023)

Biomarkers for immune checkpoint inhibitors in colorectal cancer: recent advances and future perspectives
por: Yang, Changjiang, et al.
Publicado: (2023)

Immune checkpoint inhibitors: recent progress and potential biomarkers
por: Darvin, Pramod, et al.
Publicado: (2018)

Association of Immune-Mediated Cerebellitis With Immune Checkpoint Inhibitor Therapy
por: Zurko, Joanna, et al.
Publicado: (2018)

Systemic immunological biomarkers of clinical responses in immune checkpoint blockade therapies
por: Arasanz, Hugo, et al.
Publicado: (2018)

Molecular imaging biomarkers for immune checkpoint inhibitor therapy
por: van de Donk, Pim P, et al.
Publicado: (2020)

Immune checkpoint inhibitors in renal cell carcinoma
por: Ross, Kirsty, et al.
Publicado: (2017)

Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis
por: Abu-Sbeih, Hamzah, et al.
Publicado: (2019)

Immune checkpoint inhibitors: here to stay
por: Carvalho, Filomena Marino, et al.
Publicado: (2023)

Biomarkers for Immune Checkpoint Inhibitors in Melanoma
por: Kitano, Shigehisa, et al.
Publicado: (2018)

Immune Checkpoint Inhibitor Therapy: A Boon to Elderly Patients with Advanced Melanoma?
por: Muta, Tsuyoshi
Publicado: (2018)

Early changes in soluble intracellular adhesion molecule‐1 as prognostic biomarkers to immune checkpoint inhibitor
por: Ji, Dongmei, et al.
Publicado: (2023)

Equibalancing immune‐related adverse events and anticancer activity of immune checkpoint inhibitors
por: Seeruttun, Sharvesh Raj
Publicado: (2019)

Two Types of Immune Checkpoint Inhibitor-related Pancreatitis
por: Ichiki, Tomoko, et al.
Publicado: (2021)

A Diverse Range of Cardiac Adverse Events Associated with Immune Checkpoint Inhibitor Therapy
por: Murakata, Yoshiko, et al.
Publicado: (2022)

Immune Checkpoint Inhibitors in Cancer Therapy—How Can We Improve Clinical Benefits?
por: Baxevanis, Constantin N.
Publicado: (2023)

Systemic Blood Immune Cell Populations as Biomarkers for the Outcome of Immune Checkpoint Inhibitor Therapies
por: Hernandez, Carlos, et al.
Publicado: (2020)

Targeting nuclear acid-mediated immunity in cancer immune checkpoint inhibitor therapies
por: Chen, Miaoqin, et al.
Publicado: (2020)

Biomarkers for Immune Checkpoint Inhibitor-Mediated Tumor Response and Adverse Events
por: Nakamura, Yoshiyuki
Publicado: (2019)

Vitiligo-specific soluble biomarkers as early indicators of response to immune checkpoint inhibitors in metastatic melanoma patients
por: Carbone, Maria Luigia, et al.
Publicado: (2022)

Biomarkers for predicting the efficacy of immune checkpoint inhibitors
por: Wang, Chengji, et al.
Publicado: (2022)

Biomarkers of therapeutic response with immune checkpoint inhibitors
por: Bindal, Poorva, et al.
Publicado: (2021)

Potential non-invasive biomarkers in tumor immune checkpoint inhibitor therapy: response and prognosis prediction
por: Song, Ruixia, et al.
Publicado: (2023)

Soluble and cell-based markers of immune checkpoint inhibitor-associated nephritis
por: Sise, Meghan E, et al.
Publicado: (2023)

Management of gastrointestinal adverse events induced by immune-checkpoint inhibitors
por: Wang, Zheng-Hang, et al.
Publicado: (2018)

Immune Checkpoint Inhibitors in Lung Cancer: Role of Biomarkers and Combination Therapies
por: Maung, Tun Zan, et al.
Publicado: (2020)

Cardiac Surveillance in Immune Checkpoint Inhibitor Therapy: Biomarkers Versus Imaging
por: Vallejo-Camazón, Nuria, et al.
Publicado: (2022)

The Potential Cardiotoxicity of Immune Checkpoint Inhibitors
por: Nardi Agmon, Inbar, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_0cgec7et09pih4mg7eh23sfl9e